Two DNA hexadecamers containing one central 5'-GC-3' base step have been examined by footprinting methodology in the presence and absence of actinomycin D. The results of these studies, coupled with imino proton NMR measurements indicate that the antitumor drug causes a change in DNA conformation at a distance from the actinomycin intercalation site in a molecule of sequence d[ATATATAGCTATATAT] that does not occur in d [AAAAAAAGCTTTTTTT]. The experiments demonstrate that DNase I rate enhancements associated with actinomycin D binding are caused by ligand alteration of equilibrium DNA structure.
IHTRODOCTION
DNA can adopt a variety of helical forms that depend upon local sequence and environmental factors such as ionic strength and superhelix density. Deoxyribonuclease I (DNase I) cleavage rate has been shown to respond to changes in DNA minor groove width as well as helical twist at a given base step (1) (2) (3) . We (4, 5) , and others (6, 7) , have postulated that drug associated DNase I rate enhancements are caused by induced changes in DNA structure.
This manuscript presents enzymatic evidence that d(AT) n : d(AT) n stretches change their structure in response to the underwinding stress provided by an intercalated actinomycin D molecule bound at a nearby d(GC) site, whereas similarly placed (dA) n : (dT) n sequences resist a similar conformational change. This evidence supports the hypothesis of "telestability" advanced by Wells and co-workers (8) (9) (10) ) that a ligand bound at one sequence can influence DNA structure at some distance from the binding site. This distal response will be modulated by the receptivity of a sequence to conformational change.
A dramatic example of ligand induced structural change is cooperative conversion of Z DNA to a right-handed helical configuration by intercalating compounds (11) (12) (13) (14) . Cooperative DNA binding of the non-intercalative antibiotics distamycin and netropsin (15, 16) In order to ascertain which of these mechanisms gives rise to drug associated DNase I enhancements we have studied the interaction of actinomycin D with two synthetic hexadecamer DNA duplexes. The sequences of the two 16-mers are shown below with the drug intercalation sites indicated by vertical bars. Both duplexes have identical base content but differ in sequence motif in the regions of the DNA duplexes flanking the actinomycin D binding site, studies because its interactions with DNA have been the focus of a great deal of attention (reviewed in 23, 24) . The evidence accumulated to date indicates that this drug binds DNA with a strong preference for 5 1 -GC -3 1 base pairs, in an intercalative, or pseudo-intercalative mode, with the two pentapeptide rings lying in the DNA minor groove (25) (26) (27) . The intercalated phenoxazone chromophore of the drug causes unwinding of the neighboring GC base pairs and the interaction is stabilized by two hydrogen bonds formed between the N2 amino group of the guanine residues and the carbonyl oxygen of the L-threonine residues of the cyclic pentapeptide segment of the drug. The drug is efficacious against some cancers, a powerful inhibitor of RNA transcription, and exhibits complex DNA binding kinetics.
MATERIALS AND METHODS

Oliaonucleotide
Synthesis and Manipulations, Oligonucleotides were synthesized on a Biosearch (Model 8600) DNA synthesizer in 1.0 or 15.0 uMole quantities. Hexadecamers were purified by electrophoresis through a 20%, 7.0 H urea polyacrylamide gel, visualized by backshadowing against a fluorescent TLC plate and the gel slice containing the purified oligomer excised from the gel with a razor blade. The gel slice was ground up and suspended in 1.0 ml of a 10 mM Tris/ 1.0 mM Na2EDTA (pH 7.5) solution and incubated overnight at 4'C. Subsequently, oligonucleotide was separated from the gel by passage of the slurry through silanized glass wool and then precipitated from a 0.3 M sodium acetate/ 70% ethanol solution. 15.0 uMole products were purified by HPLC on a DEAE 60-7 (Nucleogen) column. Optical density at 260 nm was used to determine concentrations. Labeling and purification of the labeled oligonucleotides has been described (5) . Labeled samples were heated to 90'C and slow cooled (l'C/min.) to avoid snap-back of the molecules to themselves.
Native acrylamide gels showed only duplex product with no contaminating hairpin structures evident (not shown) .
DNase I Digestions. Procedures used were essentially identical to those described previously (5) . Briefly, DNase I digests were performed in 8.0 ul (buffer was composed of 10 mM Tris (pH 7.5)/ 8.0 mM MgCl 2 / 2.0 mM CaCl 2 ); 2.0 ul of a 40 uM 'carrier' d[ATATAGCTATAT] duplex, 2.0 ul labeled duplex and 2.0 ul drug (or buffer) were combined and then incubated at 25"C for thirty minutes, then 2.0 ul DNase I was added to initiate the reaction. The reaction was allowed to proceed for 1.0 min. and then terminated by addition of 10.0 ul of a solution composed of 10 M urea/ 100 mM NaOH/ 50 mM Na2EDTA/ 0.1% bromophenol blue/ 0.1% xylene cyanol. All reactions were performed under conditions determined to give 80 (+/~3)% full length oligonucleotide remaining (in the drug free controls) after the reactions were terminated.
Autoradiography/ Densitometrv. X-Omat AR film was used to visualize bands after electrophoresis for periods of up to one week in the absence of intensifying screens. Densitometry was performed on a Jarrel-Ash model 23-100 densitometer coupled to an NEC microcomputer. Band intensities were obtained as integrated absorbance. This equipment has been described previously (28) . NMR Spectroscopy. Imino proton spectra were obtained on a General Electric GN-500 instrument. Samples consisted of 2 mM (single strand) DNA oligomer in the DNase I buffer described above plus 20% D 2 0. A jump-return method was used to suppress the water signal (29) . Spectra were referenced to DSS through the water peak. Actinomycin D was added to the NMR samples as a solid and allowed to eguilibrate with the oligonucleotide for at. least 30 minutes before spectra were recorded. Assignment of imino protons was accomplished by examining the temperature dependence of the protons as described (5) .
Actinomvcin D Handling. Actinomycin D was purchased from Sigma (product # A 1410) and used without further purification. An extinction coefficient of 24450 (17) were repeated in triplicate and the average ratio of cleavage rate in the presence of drug versus the no drug control for all cleaved phosphodiester linkages, in both DNA molecules, are plotted in Fig. 3 . In this representation, phosphodiester bonds inaccessible to DNase I, indicating steric blockage of the enzyme by the drug, appear as inhibition curves (ratio drops below 1.0). Conversely, phosphodiester bonds displaying drug associated enhanced cleavage appear as enhancement curves (ratio greater than 1.0). Bonds inaccessible to the enzyme are not shown but we note that the inability of the enzyme to cleave base steps at the 5' end of a duplex has been demonstrated to be a function of the mechanism by which DNase I binds to DNA (30, 31) .
Examination of the plots in Fig. 3 shows that common to both DNA duplexes is inhibition of cleavage by the drug at phosphodiester bonds between bases 7-8, 8-9, 9-10, 10-11, 11-12 and 12-13. These phosphate positions clearly are protected from DNase I as was shown in figures 1 and 2. The phosphodiester linkages-between bases 5-6 and 13-14 do not show any change within the error of our measurements in the d[AAAAAAAGCTTTTTTT] duplex. Cleavage rates of the same bonds in d [ATATATAGCTATATAT] are increased by six-fold and three-fold, respectively (note y axis scale change in these plots). The bond between basas 6-7 behaves anomalously. In the d[AAAAAAAGCTTTTTTT] duplex clear inhibition at this bond is observed while its congener in the d[ATATATAGCTATATAT] duplex showed no response to drug binding. This raises an alternative hypothesis to the three outlined above, namely, that the binding geometry of the actinomycin D molecule to the two duplexes is different. If this were the case then differing drug binding geometries could explain the different responses of the two DNA molecules to binding of the drug. In order to test this possibility a dodecamer of sequence 5' -AAAAAGCTTTTT -3' was synthesized and the imino proton NMR spectrum assigned by correlating the disappearance of proton signals with increasing temperature (Fig. 4a) . The effect of actinomycin D on the imino proton resonances was then observed. As shown in figure 4b , binding of actinomycin D to this molecule results in a decrease in the ratio of the unbound GC imino proton peak area relative to the actinomycin bound GC proton peak areas; these are split due to the asymmetry of the drug (peaks C of Fig. 4b) We have shown previously that the DNase I detected structural change is not reflected in a large change in the imino-proton chemical shifts of the (AT) n sequence (5) . to enzyme ratio (22) , can also be dismissed. An effect of this type can explain neither the sequence specificity nor the extent of the enhancements observed.
The combined observations indicate that the DNase I rate increases are due to sequence specific, actinomycin D induced, alteration in DNA structure.
A possibility we cannot exclude is that actinomycin D induces a structural change in the portion of the d(A) n :d(T) n duplex accessible to DNAse I that does not lead to altered cleavage by the enzyme.
This possibility seems remote based on the DNA structure dependence of DNAse I cleavage rate as the rate of cleavage of a phosphodiester bond is not dependent on sequence, per se, but rather sequence dependent structure (1-3) . helical repeat in the absence and an 11.7 base-pair helical repeat in the presence of supercoiling strain (33) (34) (35) . This suggests that d(AT)n : d(AT)n sequences are susceptible to underwinding and lends support to the possibility that local unwinding caused by the intercalated phenoxazone chromophore might be propagated to neighboring residues. An underwound d(AT)n : d(AT)n helix geometry might also explain the differing 6-7 phosphodiester response mentioned earlier. Additionally, the ability of actinomycin D to alter DNA structure at a distance may lead to the complex association and dissociation kinetics observed for the binding of this drug to various duplex DNA substrates (36) (37) (38) (39) (40) (41) (42) .
CONCLUSION
We have established that a structural change can be propagated through a DNA helix by a structurally disruptive DNA binding ligand, such as an intercalater, and that such an effect can be monitored with DNase I. We have suggested that unwinding induced by the drug can be transmitted to the surrounding DNA if the flanking sequence motif is receptive to unwinding.
However recent crystallographic analysis of DNase I bound to DNA (4 3) demonstrates a large DNase I induced bend in the DNA substrate.
This implicates flexibility of the double helix as important to cleavage by the enzyme molecule.
As the sequence dependence of overwinding (44, 45) has been related to DNA flexibility (46) it is possible that it is not underwinding v/hich directly causes enhanced DNase I cleavage but rather an increase in flexibility of the helix caused by underwinding.
